Free tool
FAERS Monitor: Epclusa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208341 or its brand name (Epclusa, Sofosbuvir, Velpatasvir). Reports on generic versions are filed under their own applications.
Reports
12,830
Serious
3,897
30% of reports
Hospitalization
1,446
Death reported
592
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,628
- headache2,218
- nausea1,178
- diarrhoea664
- drug ineffective558
- insomnia514
- hepatitis c413
- treatment failure337
- vomiting330
- death312
- dizziness287
- rash259
- product dose omission issue248
- abdominal discomfort239
- intentional dose omission218
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 400 |
| 2017 | 2,137 |
| 2018 | 2,222 |
| 2019 | 2,663 |
| 2020 | 1,724 |
| 2021 | 1,071 |
| 2022 | 990 |
| 2023 | 570 |
| 2024 | 449 |
| 2025 | 373 |
| 2026 | 231 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitis cSignal | 413 | 58.0 | 52.7 | 22,314 |
| intentional dose omissionSignal | 218 | 12.6 | 11.1 | 2,307 |
| treatment failureSignal | 337 | 6.7 | 6.0 | 1,626 |
| headacheSignal | 2,218 | 5.8 | 5.6 | 9,081 |
| fatigueSignal | 2,628 | 5.5 | 5.4 | 10,138 |
| insomniaSignal | 514 | 3.2 | 2.9 | 769 |
| nauseaSignal | 1,178 | 2.4 | 2.3 | 1,039 |
| abdominal discomfortSignal | 239 | 2.3 | 2.1 | 183 |
| diarrhoea | 664 | 1.7 | 1.6 | 191 |
| product dose omission issue | 248 | 1.4 | 1.2 | 26 |
| vomiting | 330 | 1.2 | 1.0 | 7 |
| rash | 259 | 1.0 | 0.9 | 0 |
| dizziness | 287 | 0.9 | 0.8 | 1 |
| drug ineffective | 558 | 0.7 | 0.6 | 80 |
| death | 312 | 0.6 | 0.5 | 90 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.